AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

ASX:MDCMedlab Clinical Stock Price, Forecast & News

A$0.22
-0.01 (-4.44 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.22
Now: A$0.22
A$0.22
50-Day Range
A$0.22
MA: A$0.21
A$0.22
52-Week Range
A$0.13
Now: A$0.22
A$0.55
Volume36,677 shs
Average VolumeN/A
Market Capitalization$50.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medlab Clinical Limited, a medical research and development facility, engages in nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is based in Alexandria, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8188 0311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.87 million
Cash FlowA$0.04 per share
Book ValueA$0.05 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$50.14 million
Next Earnings DateN/A
OptionableOptionable

Receive MDC News and Ratings via Email

Sign-up to receive the latest news and ratings for MDC and its competitors with MarketBeat's FREE daily newsletter.

Medlab Clinical (ASX:MDC) Frequently Asked Questions

How has Medlab Clinical's stock been impacted by COVID-19 (Coronavirus)?

Medlab Clinical's stock was trading at A$0.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MDC shares have increased by 2.4% and is now trading at A$0.22. View which stocks have been most impacted by Coronavirus.

Has Medlab Clinical been receiving favorable news coverage?

Media stories about MDC stock have trended negative on Wednesday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medlab Clinical earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Medlab Clinical.

Who are some of Medlab Clinical's key competitors?

What other stocks do shareholders of Medlab Clinical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medlab Clinical investors own include iSignthis (ISX), FBR (FBR), Evolve Education Group (EVO), Dacian Gold (DCN), CCP Technologies (CT1), Bingo Industries (BIN), BOD Australia (BDA), Afterpay Touch Group (APT), Alkane Resources (ALK) and Auscann Group (AC8).

Who are Medlab Clinical's key executives?

Medlab Clinical's management team includes the following people:
  • Dr. Sean Michael Hall, MD, CEO & Director
  • Mr. Alan Dworkin, CFO & Company Sec.
  • Dr. Luis Vitetta BSc(Hons), Grad Dip, Ph.D., Grad Dip Nutr, Director of Medical Research
  • Dr. David A. Rutolo, Director of Science
  • Mr. Paul Vilner, Director of Commercial Operations

What is Medlab Clinical's stock symbol?

Medlab Clinical trades on the ASX under the ticker symbol "MDC."

What is Medlab Clinical's stock price today?

One share of MDC stock can currently be purchased for approximately A$0.22.

How big of a company is Medlab Clinical?

Medlab Clinical has a market capitalization of $50.14 million and generates $4.87 million in revenue each year.

What is Medlab Clinical's official website?

The official website for Medlab Clinical is www.medlab.co.

How can I contact Medlab Clinical?

The company can be reached via phone at 61 2 8188 0311.

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.